[1]CurrentPatentAssignee:BAYERAG-TW2016/7950,2016,A
[2]Härter,Michael;Kalthof,Bernd;Delbeck,Martina;Lustig,Klemens;Gerisch,Michael;Schulz,Simone;Kast,Raimund;Meibom,Daniel;Lindner,Niels[EuropeanJournalofMedicinalChemistry,2019,vol.163,p.763-778]
[1]CurrentPatentAssignee:BAYERAG-TW2016/7950,2016,A
[2]CurrentPatentAssignee:BAYERAG-TW2016/7950,2016,A
[3]Härter,Michael;Kalthof,Bernd;Delbeck,Martina;Lustig,Klemens;Gerisch,Michael;Schulz,Simone;Kast,Raimund;Meibom,Daniel;Lindner,Niels[EuropeanJournalofMedicinalChemistry,2019,vol.163,p.763-778]
[1]CurrentPatentAssignee:BAYERAG-TW2016/7950,2016,A
[2]CurrentPatentAssignee:BAYERAG-TW2016/7950,2016,A
[3]Härter,Michael;Kalthof,Bernd;Delbeck,Martina;Lustig,Klemens;Gerisch,Michael;Schulz,Simone;Kast,Raimund;Meibom,Daniel;Lindner,Niels[EuropeanJournalofMedicinalChemistry,2019,vol.163,p.763-778]
[1]CurrentPatentAssignee:BAYERAG-TW2016/7950,2016,A
[1]CurrentPatentAssignee:BAYERAG-TW2016/7950,2016,A
[2]Härter,Michael;Kalthof,Bernd;Delbeck,Martina;Lustig,Klemens;Gerisch,Michael;Schulz,Simone;Kast,Raimund;Meibom,Daniel;Lindner,Niels[EuropeanJournalofMedicinalChemistry,2019,vol.163,p.763-778]
Title: Härter M, et al. Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure. Eur J Med Chem. 2019 Feb 1;163:763-778.